E. Neuhart

发表

First in man study of EP217609, a new long-acting, neutralisable parenteral antithrombotic with a dual mechanism of action

M. Petitou, E. Fuseau, P. V. van Giersbergen, 2016, European Journal of Clinical Pharmacology.

Neutralization of EP217609, a new dual-action FIIa/FXa anticoagulant, by its specific antidote avidin: a phase I study

M. Petitou, E. Fuseau, P. Giersbergen, 2016, European Journal of Clinical Pharmacology.

EP42675, a synthetic parenteral dual‐action anticoagulant: pharmacokinetics, pharmacodynamics, and absence of interactions with antiplatelet drugs

M. Petitou, E. Fuseau, P. Giersbergen, 2014, Journal of thrombosis and haemostasis : JTH.

In vitro comparison of the novel, dual-acting FIIa/FXa-inhibitor EP217609C101, unfractionated heparin, enoxaparin, and fondaparinux in preventing cardiac catheter thrombosis

K. Werdan, A. Schlitt, M. Buerke, 2013, Journal of Thrombosis and Thrombolysis.

Effect of the urotensin receptor antagonist palosuran on albuminuria in hypertensive patients with type 2 diabetic nephropathy: results from the PROLONG proof-of-concept study

S. Hadjadj, G. Remuzzi, H. Krum, 2008 .

A Multicenter Randomized Double-blind Study of Enoxaparin Compared with Unfractionated Heparin in the Prevention of Venous Thromboembolic Disease in Elderly In-patients Bedridden for an Acute Medical Illness

J. Bergmann, E. Neuhart, Jean-Fraçois Bergmann, 1996, Thrombosis and Haemostasis.

Effect of the Urotensin Receptor Antagonist Palosuran in Hypertensive Patients With Type 2 Diabetic Nephropathy

S. Hadjadj, G. Remuzzi, H. Krum, 2010, Hypertension.

SUBCUTANEOUS ADMINISTRATION OF A LOW MOLECULAR WEIGHT HEPARIN (CY 222) COMPARED WITH SUBCUTANEOUS ADMINISTRATION OF STANDARD HEPARIN IN PATIENTS WITH ACUTE DEEP VEIN THROMBOSIS

J. Bassand, R. Faivre, J. Maurat, 1987, Thrombosis and Haemostasis.

Fibrinolytic and thrombolytic parameters in patients with deep vein thrombosis treated by low molecular weight and standard heparin.

J. Soria, C. Soria, J. Bassand, 1989, Seminars in thrombosis and hemostasis.

The hemodynamic and neurohormonal effects of low doses of tezosentan (an endothelin A/B receptor antagonist) in patients with acute heart failure

C. Richter, K. Stangl, Z. Vered, 2004, European journal of heart failure.

Effect of heparin and enoxaparin on platelet interaction with fibrin clots.

J. Soria, C. Soria, P. Steg, 1992, Thrombosis research.

Valsartan in acute myocardial infarction trial (VALIANT): rationale and design.

M. Pfeffer, R. Califf, J. McMurray, 2000, American heart journal.